PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5195405

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AERAS	10/01/2018

RECEIVING PARTY DATA

Name:	INTERNATIONAL AIDS VACCINE INITIATIVE, INC.
Street Address:	125 BROAD STREET
Internal Address:	9TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10004

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	8658136

CORRESPONDENCE DATA

Fax Number: (610)640-1965

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6106512277
Email: chill@stradley.com

Correspondent Name: PAUL K. LEGAARD, ESQ.

Address Line 1: 30 VALLEY STREAM PARKWAY

Address Line 2: STRADLEY RONON STEVENS & YOUNG, LLP


Address Line 4: MALVERN, PENNSYLVANIA 19355-1481

ATTORNEY DOCKET NUMBER:	189107.00841 (3095)
NAME OF SUBMITTER:	CATHERINE HILL
SIGNATURE:	/Cathy1/
DATE SIGNED:	10/18/2018

Total Attachments: 19

source=Aeras-IAVI Assignment#page1.tif source=Aeras-IAVI Assignment#page2.tif source=Aeras-IAVI Assignment#page3.tif source=Aeras-IAVI Assignment#page4.tif

PATENT 505148638 REEL: 047219 FRAME: 0547



ASSIGNMENT OF PATENTS AND TRADEMARKS

This Assignment of Patents and Trademarks (the "Assignment") is entered into effective as of October 1, 2018 by and between Aeras, a not for profit corporation organized under the laws of the District of Columbia ("Assignor"), and International AIDS Vaccine Initiative, Inc., a not for profit corporation organized under the laws of the State of Delaware ("Assignee").

WHEREAS, Assignor and Assignee are parties to that certain Asset Transfer Agreement dated as of September 30, 2018 (the "Transfer Agreement"), pursuant to which Assignor has agreed to sell, convey, assign, transfer and deliver to Assignee: (i) all of Assignor's right, title and interest in and to the patents and patent applications listed on Schedule A hereto (collectively, the "Patents"), and (ii) all of Assignor's right, title and interest in and to the trademarks, service marks, trademark and service mark applications and trademark and service mark registrations listed on Schedule A, including all related common law rights with respect thereto (collectively, the "Trademarks"); and

WHEREAS, Assignor desires to convey assign, transfer and deliver to Assignee, and Assignee desires to purchase, acquire, receive and accept from Assignor, all of Assignor's right, title and interest in and to the Patents and Trademarks.

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows:

- 1. <u>Assignment</u> Assignor does hereby sell, convey, assign, transfer and deliver unto Assignee all of Assignor's worldwide right, title and interest in, to and under:
 - a. All of Assignor's worldwide right, title and interest in, to and under the Patents, any and all continuations, continuations-in-part, divisions, foreign counterparts, reexaminations, reissues, renewals and extensions thereof that may hereafter be secured under the laws now or hereafter in effect in the United States and/or in any other jurisdiction, and together with all rights to sue and recover for any past infringements of any of the Patents, the same to be held and enjoyed by the Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment of the Patents not been made; and
 - b. All of Assignor's worldwide right, title and interest in and under the Trademarks throughout the world, including all registrations and applications thereof and the goodwill symbolized thereby, and all causes of actions, claims and demands or other rights for, or arising from, any past, present, and future infringement or other violation of the Trademarks, the same to be held and enjoyed by the Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment of the Trademarks not been made.
- 2. <u>Further Assurances</u>. Assignor further agrees, without further consideration, to cooperate with the Assignee and to execute and deliver, or use its best efforts to cause to

be executed and delivered, all such other instruments, including instruments of conveyance, assignment and transfer, and to take all such other actions as the Assignee may reasonably request from time to time, consistent with the terms of this Assignment and the Transfer Agreement, in order to effectuate the provisions and purposes of this Assignment and the transactions contemplated hereby and to permit Assignee to be duly recorded as the registered owner and proprietor of the rights hereby conveyed.

- 3. Counterparts: Effectiveness. This Assignment may be assigned in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Assignment shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. For the convenience of the parties, any number of counterparts hereof may be executed, each such executed counterpart shall be deemed and original and all such counterparts together shall constitute one and the same instrument. Facsimile transmission (including the e-mail delivery of document in .pdf or similar format) of any signed original counterpart or retransmission of any signed facsimile transmission shall be deemed the same as the delivery of an original.
- 4. <u>Headings</u>. The descriptive headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Assignment.
- 5. Governing Law: Jurisdiction. This Assignment will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the United State federal law preempts New York law, in which case United States federal law (including, without limitation, copyright, patent and federal trademark law) shall apply, without regard to all choice of law and conflicts of law rules.
- 6. Severability. If any term or other provision of this Assignment is invalid, illegal or incapable of being enforced by any law or public policy, all other terms and provisions of this Assignment shall nevertheless remain in full force and effect so long as the economic and legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Assignment so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transaction contemplated hereby are consummated as originally contemplated to the greatest extent possible, and if such modification is not possible, such provision shall be severed from this Assignment, and in either case the validity, legality and enforceability of the remaining provisions of this Assignment shall not in any way be affected or impaired thereby.

(Remainder of Page Intentionally Left Blank)

IN WITNESS WHEREOF, the undersigned have caused this Assignment and Assumption to be duly executed effective as of the date first set forth above.

ASSIGNOR:	ASSIGNEE:
Aeras	International AIDS Vaccine Initiative, Inc.
By: <u>Jacqueline E. Shea, Ph.D.</u>	Ву:
Name: CEO, Aeras	Name:
Title:	Title:
Date: 30th Sentember 2018	Date:

IN WITNESS WHEREOF, the undersigned have caused this Assignment and Assumption to be duly executed effective as of the date first set forth above.

Aeras International AIDS Vaccine Initia	
By:	
Name: <u>Labeeb Abboud</u>	
Title: Title: General Counsel & Senio	or Vice Presiden
Date: Date: September 28, 2018	

SCHEDULE A ASSIGNED PATENTS AND TRADEMARKS

PATENTS:

Table A.4.1 Family 002

	189107.00208		189107.00207		189107.00206		189107.00205		189107.00204		189107.00203		189107.00231		189107.00221		Number	Docket
Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced	Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced	Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced	Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced	Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced	Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced	Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced	Ability To Escape The Endosome	Recombinant BCG Strains With Enhanced			Title
	AU		ΑP		PE		WT		JP		ĘP		SN		SN			Country
(11/23/05)	2005338353	(11/23/05)	2007/004033	(11/30/05)	1391.2005	(11/29/05)	20050141904	(11/23/05)	2007-545507	(11/23/05)	05858631.4	(12/31/09)	12/650,606	(5/31/07)	11/755,936	(Filing date)	Number	Application
										(9/5/07)	EP 1827504	(9/16/10)	2010-0233213	(4/24/08)	2008-0095794	(Publication date)	Number	Publication
(7/28/11)	2005338353					(10/11/14)	1456057	(3/11/15)	5713523	(5/11/11)	EP 1827504	(10/25/11)	8,043,857	(2/23/10)	7,666,656	(Issue Date)	Number	Patent
	Issued		Allowed		Pending		Issued			Status								

	(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Issued	EP 1827504		EP 1827504	BE	Recombinant BCG Strains With Enhanced	189107.00235
	(9/25/08)		(11/23/05)		Ability To Escape The Endosome	
Issued	2007/04765		2007/04765	ZA	Recombinant BCG Strains With Enhanced	189107.00229
	(6/25/09)		(11/23/05)		Ability To Escape The Endosome	
Issued	14103		1200700206	OA	Recombinant BCG Strains With Enhanced	189107.00228
	(5/31/07)		(11/23/05)		Ability To Escape The Endosome	
Issued	2007/820		2007/820	NG	Recombinant BCG Strains With Enhanced	189107.00227
	(2/8/11)		(11/23/05)		Ability To Escape The Endosome	
Issued	MX 283767		2007/006551	×	Recombinant BCG Strains With Enhanced	189107.00226
			(11/23/05)			
	(11/7/13)		7015173		Ability To Escape The Endosome	
Issued	10-1329323		10-2007-	Ŕ	Recombinant BCG Strains With Enhanced	189107.00225
	(1/17/14)		(11/23/05)		Ability To Escape The Endosome	
Issued	258525		3677/2007	Z	Recombinant BCG Strains With Enhanced	189107.00219
			(11/23/05)		Ability To Escape The Endosome	
Allowed			W-00200701728	Ð	Recombinant BCG Strains With Enhanced	189107.00218
	(10/30/09)		(11/23/05)		Ability To Escape The Endosome	
Issued	012434		200701128	ΕA	Recombinant BCG Strains With Enhanced	189107.00217
	(6/26/13)					
	1438.3		(6/1/07)		Ability To Escape The Endosome	
Issued	ZL20058004		200580041438.3	CN	Recombinant BCG Strains With Enhanced	189107.00216
	(10/29/13)		(11/23/05)		Ability To Escape The Endosome	
Issued	2,589,204		2,589,204	CA	Recombinant BCG Strains With Enhanced	189107.00215
					Endosomes And Vaccine Preparation	
			(11/23/05)		Mycobacterium To Escape From	
Allowed			PI 0518091-0	BR	Mycobacterium, Method Of Enabling A	189107.00209
	(Issue Date)	(Publication date)	(Filing date)			
	Number	Number	Number			Number
Status	Patent	Publication	Application	Country	Title	Docket

Strains With Enhanced CH EP 1827504 (Filling date) (Publication date) (Issue Date) Strains With Enhanced CH EP 1827504 EP 1827504 Issued The Endosome DE EP 1827504 EP 1827504 Issued The Endosome DK EP 1827504 EP 1827504 Issued The Endosome DK EP 1827504 EP 1827504 Issued The Endosome ES EP 1827504 EP 1827504 Issued The Endosome ES EP 1827504 EP 1827504 Issued The Endosome ES EP 1827504 EP 1827504 Issued The Endosome FR EP 1827504 EP 1827504 Issued The Endosome GB EP 1827504 EP 1827504 Issued Strains With Enhanced GB EP 1827504 EP 1827504 Issued The Endosome (11/23/05) EP 1827504 Issued Strains With Enhanced IT EP 1827504 EP 1827504 Issued The Endosome		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Number Number Number CH (Filing date) (Publication date) (Issue Date) CH EP 1827504 (EP 1827504 (5/11/11) DE EP 1827504 (EP 1827504 (5/11/11) DK EP 1827504 EP 1827504 (5/11/11) ES EP 1827504 EP 1827504 (5/11/11) ES EP 1827504 EP 1827504 (5/11/11) FR EP 1827504 EP 1827504 (5/11/11) GB EP 1827504 EP 1827504 (5/11/11) IT EP 1827504 EP 1827504 (5/11/11) EP 1827504 (5/11/11) EP 1827504 IT EP 1827504 (5/11/11) EP 1827504 (5/11/11) (5/11/11)	Issued	EP 1827504		EP 1827504	Z	Recombinant BCG Strains With Enhanced	189107.00248
Number Number Number Number (filing date) (fili		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Wumber Number Number CH EP 1827504 EP 1827504 EP 1827504 DE EP 1827504 (5/11/11) EP 1827504 DK EP 1827504 (5/11/11) EP 1827504 ES EP 1827504 (5/11/11) EP 1827504 ES EP 1827504 (5/11/11) EP 1827504 FR EP 1827504 (5/11/11) EP 1827504 GB EP 1827504 (5/11/11) EP 1827504 GB EP 1827504 (5/11/11) EP 1827504	Issued	EP 1827504		EP 1827504	⊐	Recombinant BCG Strains With Enhanced	189107.00247
Wumber Number Number CH EP 1827504 EP 1827504 EP 1827504 DE EP 1827504 (5/11/11) EP 1827504 DK EP 1827504 EP 1827504 (5/11/11) DK EP 1827504 EP 1827504 EP 1827504 ES EP 1827504 EP 1827504 EP 1827504 FR EP 1827504 EP 1827504 EP 1827504 GB EP 1827504 EP 1827504 EP 1827504		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Wumber Number Number Number CH EP 1827504 (Publication date) (Issue Date) DE EP 1827504 (5/11/11) DK EP 1827504 (5/11/11) DK EP 1827504 (5/11/11) ES EP 1827504 (5/11/11) ES EP 1827504 (5/11/11) FR EP 1827504 (5/11/11) FR EP 1827504 (5/11/11) ES EP 1827504 (5/11/11) ES EP 1827504 (5/11/11)	Issued	EP 1827504		EP 1827504	GB	Recombinant BCG Strains With Enhanced	189107.00246
Wumber Number Number CH EP 1827504 EP 1827504 EP 1827504 DE EP 1827504 EP 1827504 EP 1827504 DK EP 1827504 EP 1827504 EP 1827504 ES EP 1827504 EP 1827504 EP 1827504 ES EP 1827504 EP 1827504 EP 1827504 FR EP 1827504 EP 1827504 EP 1827504 EF EP 1827504 EP 1827504 EP 1827504		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Wumber Number Number CH EP 1827504 EP 1827504 EP 1827504 DE EP 1827504 (5/11/11) DK EP 1827504 (5/11/11) DK EP 1827504 EP 1827504 ES EP 1827504 (5/11/11) ES EP 1827504 (5/11/11) ES EP 1827504 (5/11/11)	Issued	EP 1827504		EP 1827504	FR	Recombinant BCG Strains With Enhanced	189107.00245
Wumber Number Number CH (FHing date) (Publication date) (Issue Bate) CH EP 1827504 EP 1827504 (5/11/11) DE EP 1827504 EP 1827504 EP 1827504 DK EP 1827504 (5/11/11) EP 1827504 ES EP 1827504 EP 1827504 EP 1827504 ES EP 1827504 EP 1827504 EP 1827504		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Number Number Number Number CH [Filing date] {Publication date} [Issue Date] CH EP 1827504 EP 1827504 [5/11/11) DE EP 1827504 EP 1827504 EP 1827504 DK EP 1827504 EP 1827504 EP 1827504 DK EP 1827504 EP 1827504 EP 1827504 CM (11/23/05) EP 1827504 EP 1827504	Issued	EP 1827504		EP 1827504	ES	Recombinant BCG Strains With Enhanced	189107.00239
Number Number Number Number CH (Filing date) (Publication date) (Issue Date) CH EP 1827504 EP 1827504 (5/11/11) DE EP 1827504 EP 1827504 EP 1827504 DK EP 1827504 EP 1827504 EP 1827504		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Number Number<	Issued	EP 1827504		EP 1827504	P	Recombinant BCG Strains With Enhanced	189107.00238
CH FFIIIng date) (FIIIng date) (Publication date) (Issue Date) CH EP 1827504 EP 1827504 EP 1827504 DE EP 1827504 EP 1827504 EP 1827504		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Number Number Number Number CH EP 1827504 EP 1827504 EP 1827504 (5/11/11) EP 1827504 EP	Issued	EP 1827504		EP 1827504	DE	Recombinant BCG Strains With Enhanced	189107.00237
Mumber Number Number (Filing date) (Publication date) (Issue Date) CH EP 1827504 EP 1827504		(5/11/11)		(11/23/05)		Ability To Escape The Endosome	
Number (Publication date)	Issued	EP 1827504		EP 1827504	유	Recombinant BCG Strains With Enhanced	189107.00236
Number		(Issue Date)	(Publication date)	(Filing date)			
		Number	Number	Number			Number
Title Country Application Publication Patent Status	Status	Patent	Publication	Application	Country	Title	Docket

Table A.4.2 Family 003

			189107.00301	Docket Number
Mycobacteria	Overexpression Of Antigens In	Selectable Marker And	Transformed Bacterium Lacking	eltit
			SN	Country
		(11/29/05)	11/288,424	Application Number (Filing date)
		(6/8/06)	2006-0121054	Publication Number (Publication date)
		(12/1/09)	7,625,572	Patent Number (Issue Date)
			Issued	Status

189107.00308	189107.00307	189107.00306	189107.00305	189107.00304	189107.00303	189107.00311	Docket Number
Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	Transformed Bacterium Or Progeny Thereof, Method Of Transforming A Bacterium, Transformed Mycobacterium Or Progeny Thereof And Vaccine Comprising A Transformed Mycobacterium Or Progeny Thereof	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	Title
CA	BR	AU	AP	JP	EP	SN	Country
2,587,507 (11/29/05)	PI 0518080-5 (11/29/05)	2005312062 (11/29/05)	2007/004021 (11/29/05)	2007-544419 (11/29/05)	05852317.6 (11/29/05)	11/755,768 (5/31/07)	Application Number (Filing date)
					EP 1817061 (8/15/07)	2008-0286852 (11/20/08)	Publication Number (Publication date)
2,587,507 (11/19/13)		2005312062 (3/1/12)	AP 2869 (3/31/14)	5461776 (1/24/14)	EP 1817061 (7/27/11)	7,829,104 (11/9/10)	Patent Number (Issue Date)
Issued	Allowed	Issued	Issued	Issued	Issued	Issued	Status

CN 200580041437.9 Pauline Pauline CN 200580041437.9 Pauline CN 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 200580041437.9 2012182 2		(9/25/08)		(11/29/05)		Mycobacteria	
COMINITY Number	Issue	2007/04764		2007/04764	ΑZ	Electroporation Of Mycobacterium	189107.00327
COMINITY Pappinication Fubilisation date) CN Number (Filing date) Publication date)		(2/20/00/		(11/27/07)		Mycobacteria or Aliagens in	
COUNTY Number Number (Issue Date)	Issue	13805		120700206	OA	Electroporation Of Mycobacterium And Overeypression Of Antigens In	189107.00326
Country Number Number (Issue Usite)						Mycobacteria	
Country Number Number (Issue United		(5/23/07)		(11/29/05)		And Overexpression Of Antigens In	
COUNTRY Number Number Humin duty Falent Warning	Issue	17063		302/07	NG	Electroporation Of Mycobacterium	189107.00325
CAUSINITY Physicalism Patient Multiple CN (Filing date) (Publication date) CN 200580041437.9 200580041437.9 200580041437.9 (4/3/13) 200580041437.9 (4/3/13) 200580041437.9 (4/3/13) (4/1/14)						Mycobacteria	
CAMINITY Priprication Practice Number (Issue Date)		(8/3/10)		(11/29/05)		And Overexpression Of Antigens In	
Country Repairement Franticular Fran	Issu	277803		2007/006552	××	Electroporation Of Mycobacterium	189107.00319
Countility Number Number Hassue Date)						Mycobacteria	
Course Publication Fatelite Mainter		(4/1/14)		(11/29/05)		And Overexpression Of Antigens In	
CN 200580041437.9 CN 200580041437.9 CN 200701130 (11/29/05) CN 3686/DELNP/2007 CN 3686/DELNP/2007 (11/29/05) CN 3686/DELNP/2007 CN CN CN CN CN CN CN C	lssu	10-1382215		10-2007-7015172	Ŝ	Electroporation Of Mycobacterium	189107.00318
CN 200580041437.9 CN 200580041437.9 CN 200701130 (11/29/05) CN 3686/DELNP/2007 CN 3686/DELNP/2007 CN COUNTY CO						Mycobacteria	
CN 200580041437.9 CN 200580041437.9 CN 200701130 (11/29/05) EA (11/29/05) CI (11/29/05) CI (3/4/15)		(8/20/14)		(11/29/05)		And Overexpression Of Antigens In	
CN 200580041437.9 CN 200701130 EA (11/29/05) CI (11/29/05) CI (20070037928 CI (20070136) CI	lssu	262398		3686/DELNP/2007	Z	Electroporation Of Mycobacterium	189107.00317
CN 200580041437.9 CN (6/1/07) (Publication date) 200580041437.9 ZL 200580041437.9 (4/3/13) EA 200701130 (11/29/05) (11/29/						Mycobacteria	
CN 200580041437.9 Fubilication date) CN 200701130 EA 200701726 ID W-00200701726 ID W-0000037928 ID W-00000037928 ID W-0000037928 ID W-0000037928 ID W-0000037928 ID W-0000037928 ID W-0000037928 ID W-0000037928 ID W-00000037928 ID W-000000037928 ID W-00000000000000000000000000000000000		(3/4/15)		(11/29/05)		And Overexpression Of Antigens In	
CN 200580041437.9 CN (6/1/07) (6/1/29/05) EA 200701130 (11/29/05) (11/29/05) (11/29/05) (8/28/09) (8/28/09)	Issu	IDP000037928		W-00200701726	D	Electroporation Of Mycobacterium	189107.00316
CN 200580041437.9 EA 200701130 EA (11/29/05) (11/29/05) (8/28/09) (8/28/09)						Mycobacteria	
Countilly Publication Futurication Fraction Publication date (Issue Date)		(8/28/09)		(11/29/05)		And Overexpression Of Antigens In	
CN 200580041437.9 (6/1/07) (6/1/07) (6/3/13) (4/3/13) (4/3/13) (4/3/13)	lssu	012182		200701130	ΕA	Electroporation Of Mycobacterium	189107.00315
County Pappincation Patent Number (Issue Date)		(4/3/13)				Mycobacteria	
CN 200580041437.9 Fubilication Fateric Number (fissue Date) CN 200580041437.9 Fubilication date) CN 200580041437.9		200580041437.9		(6/1/07)		And Overexpression Of Antigens In	
Rumber Publication Facent Winder Number Number (Issue Date) (Filing date) (Publication date)	Issu	ZL		200580041437.9	CN	Electroporation Of Mycobacterium	189107.00309
Rumber Number (Issue Date)			(Publication date)	(Filing date)			
социну журиканан ғызиканан ғасыстанан		(Issue Date)	Number	Number			
Address of the contract of the	Status	Patent Number	Publication	Application	Agunoo	Title	Docket Number

EP 1817061 EP 1817061 Issued (11/29/05) (7/27/11) Issued (P 1817061 EP 1817061 Issued (11/29/05) EP 1817061 Issued	ES EP (11 (11 (11 (11 (11 (11 (11 (11 (11 (1	Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium	189107.00339 189107.00345 189107.00346
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11)		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	189107.00339 189107.00345
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11)		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In	189107.00339 189107.00345
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 EP 1817061		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium	189107.00339 189107.00345
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11)		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	189107.00339
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11)		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In	189107.00339
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria Electroporation Of Mycobacterium	189107.00339
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11)		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061 (7/27/11)		Mycobacteria Electroporation Of Mycobacterium And Overexpression Of Antigens In	
EP 1817061 (7/27/11) EP 1817061 (7/27/11) EP 1817061		Mycobacteria Electroporation Of Mycobacterium	
EP 1817061 (7/27/11) EP 1817061 (7/27/11)		Mycobacteria	189107.00338
EP 1817061 (7/27/11) EP 1817061 (7/27/11)			
EP 1817061 (7/27/11) EP 1817061		And Overexpression Of Antigens In	
EP 1817061 (7/27/11)		Electroporation Of Mycobacterium	189107.00337
EP 1817061 (7/27/11)		Mycobacteria	
EP 1817061	(11	And Overexpression Of Antigens In	
	DK EP :	Electroporation Of Mycobacterium	189107.00336
		Mycobacteria	
(11/29/05) (7/27/11)	(11	And Overexpression Of Antigens In	
EP 1817061 EP 1817061 Issued	DE EP :	Electroporation Of Mycobacterium	189107.00335
		Mycobacteria	
(11/29/05) (7/27/11)	(11	And Overexpression Of Antigens In	
EP 1817061 EP 1817061 Issued	CH EP :	Electroporation Of Mycobacterium	189107.00329
		Mycobacteria	
(11/29/05) (7/27/11)	(11	And Overexpression Of Antigens In	
EP 1817061 EP 1817061 Issued	BE EP :	Electroporation Of Mycobacterium	189107.00328
(Filing date) (Publication date)	(Filli		
Number (Issue Date)	2		
Application Publication Patent Number Status	Country Apr	Title	Docket Number

Table A.4.3 Family 004

					Recombinant Double-Stranded RNA Nucleocapsids And Uses Thereof	
	(9/25/08)		(11/23/05)		For Generation And Production Of	
Issued	2007/04766		2007/04766	ZA	Bacterial Packaging Strains Useful	189107.00406
					Nucleocapsids And Uses Thereof	
					Recombinant Double-Stranded RNA	
	(8/10/11)		(5/30/07)		For Generation And Production Of	
Issued	ZL200580041153.X		200580041153.X	CN	Bacterial Packaging Strains Useful	189107.00405
					Nucleocapsids And Uses Thereof	
					Recombinant Double-Stranded RNA	
	(11/8/11)	(6/1/06)	(11/23/05)		For Generation And Production Of	
Issued	8,053,568	2006-0115493	11/284,817	SN	Bacterial Packaging Strains Useful	189107.00411
		(Publication date)	(Filing date)			
	(Issue Date)	Number	Number			Number
Status	Patent Number	Publication	Application	Country	Title	Docket

Table A.4.4 Family 005

		189107.00501	Docket Number
(HIV) Envelope Glycoproteins And The M9 Scorpion Toxin	Recombinant Human Immunodeficiency Virus	Webbed Immunogens Comprising	Title
		SN	Country
	(6/2/06)	11/445,455	Application Number (Filing date)
	(1/18/07)	2007-0014814	Publication Number (Publication date)
	(5/26/09)	7,537,769	Patent Number (Issue Date)
		Issued	Status

Table A.4.5 Family 006

	189107.00605	Docket Number
Using Tyloxapol	Process For Stabilization Of Bacterial Cells	Title
	ZA	Country
(9/26/06)	2008/03526	Application Number (Filing date)
		Publication Number (Publication date)
(10/28/09)	2008/03526	Patent Number (Issue Date)
	Issued	Status

Table A.5.6 Family 007

189107.00703	189107.00711	189107.00701	Docket Number
Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	Fite
EP	Sn	NS	Country
08853526.5 (11/26/08)	12/618,037 (11/13/09)	11/945,680 (11/27/07)	Application Number (Filing date)
EP 2235163 (10/6/10)	2011-0117133 (5/19/11)	2009-0136534 (5/28/09)	Publication Number (Publication date)
EP 2235163 (12/12/1)3	8,361,482 (1/29/13)	7,670,609 (3/2/10)	Patent Number (Issue Date)
Issued	Issued	Issued	Status

					Disease	
					In All Physiological Stages Of Infection And	
					Responses To Mycobacterium Tuberculosis	
	(12/12/13)		(12/12/13)		Vaccine Designed To Elicit Immune	
Issued	EP 2235163		EP 2235163	PK	Novel Recombinant BCG Tuberculosis	189107.00715
					Disease	
					In All Physiological Stages Of Infection And	
					Responses To Mycobacterium Tuberculosis	
	(12/12/13)		(12/12/13)		Vaccine Designed To Elicit Immune	
Issued	EP 2235163		EP 2235163	DE	Novel Recombinant BCG Tuberculosis	189107.00709
					Disease	
					In All Physiological Stages Of Infection And	
					Responses To Mycobacterium Tuberculosis	
	(12/12/13)		(12/12/13)		Vaccine Designed To Elicit Immune	
Issued	EP 2235163		EP 2235163	BE	Novel Recombinant BCG Tuberculosis	189107.00708
					Mycobacterium Tuberculosis	
	(9/28/11)		(11/26/08)		Eliciting Immune Responses To	
Issued	2010/04475		2010/04475	ZA	Recombinant BCG Tuberculosis Vaccine For	189107.00707
					Disease	
					In All Physiological Stages Of Infection And	
					Responses To Mycobacterium Tuberculosis	
			(11/26/08)		Vaccine Designed To Elicit Immune	
Pending			4543/2010	Z	Novel Recombinant BCG Tuberculosis	189107.00706
					Mycobacterium Tuberculosis	
	(11/23/16)		(11/26/08)		Eliciting Immune Responses To	
Issued	ZL200880124600.1		200880124600.1	CN	Recombinant BCG Tuberculosis Vaccine For	189107.00705
		date)	C			
	timent many	(Publication	(Filing date)			
J. C.	(Issue Date)	Number	Number	Council		
2	Patent Mumher	Publication	Annlication	Country	Title	Darket Mumber Title

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00716	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	ES	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00717	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	FR	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00718	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	GB	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00719	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	ІТ	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00725	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	NL	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued

Table A.4.7 Family 008

	Docket Number	Title	Country	Application Number Filing date	Publication Number (Publication date)	Patent Number (Issue Date)	Status
Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors of The Eukaryotic Type I Interferon Response (9/12/07) (3/12/09) (10/27/09) Methods To Increase Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 12/558,137 2010-0003219 7,883,696 Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 12/564,830 2011-0086066 8,414,884 Methods To Increase Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 12/964,830 2011-0086066 8,414,884 Methods To Increase Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 13/858,289 2013-0224242 8,658,136 Methods To Increase Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 13/858,289 2013-0224242 8,658,136 Methods To Increase The Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 13/858,289 2013-0224242 8,658,136 Methods To Increase The Transgene Expressing Suppressors Of Eukaryotic Type I Interferon Response JP 2010-524977 5665541 Expression From Bacterial-Based Delivery Systems By Co-Expressing System By Co-Expressing System System System	189107.00801	Methods To Increase Transgene	SU	11/854,027	2009-0068222	7,608,256	Issued
Delivery Systems By Co-Expressing US 12/558,137 2010-0003219 7,883,696 Suppressors Of The Eukaryotic Type I Interferon Response US 12/558,137 2010-0003219 7,883,696 Methods To Increase Transgene US (9/11/09) (1/7/10) (2/8/11) Expression From Bacterial-Based US 12/964,830 2011-0086066 8,414,884 Delivery Systems By Co-Expressing US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Delivery Systems By Co-Expressing US 13/858,289 2013-0224242 8,658,136 Suppressors Of The Eukaryotic Type I 13/858,289 2013-0224242 8,658,136 Methods To Increase The Transgene US 13/858,289 2013-0224242 8,658,136 Suppressors Of The Eukaryotic Type I 10 10 <td< td=""><td></td><td>Expression From Bacterial-Based</td><td></td><td>(9/12/07)</td><td>(3/12/09)</td><td>(10/27/09)</td><td></td></td<>		Expression From Bacterial-Based		(9/12/07)	(3/12/09)	(10/27/09)	
Suppressors Of The Eukaryotic Type I US 12/558,137 2010-0003219 7,883,696 Methods To Increase Transgene US (9/11/09) (1/7/10) (2/8/11) Expression From Bacterial-Based US (9/11/09) (1/7/10) (2/8/11) Delivery Systems By Co-Expressing US 12/964,830 2011-0086066 8,414,884 Suppression From Bacterial-Based US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Delivery Systems By Co-Expressing US 13/858,289 2013-0224242 8,658,136 Methods To Increase The Transgene US 13/858,289 2013-0224242		Delivery Systems By Co-Expressing					
Interferon Response		Suppressors Of The Eukaryotic Type I					
Methods To Increase Transgene US 12/558,137 2010-0003219 7,883,696 Expression From Bacterial-Based (9/11/09) (1/7/10) (2/8/11) Delivery Systems By Co-Expressing (9/11/09) (1/7/10) (2/8/11) Suppressors Of The Eukaryotic Type I Interferon Response US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Delivery Systems By Co-Expressing (4/8/13) (8/29/13) (2/25/14) Methods To Increase The Transgene JP 2010-524977 5665541 Expression From Bacterial-Based (9/12/08) (12/19/14) Delivery Systems By Co-Expressing (12/19/1		Interferon Response					
Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response (9/11/09) (1/7/10) (2/8/11) Methods To Increase Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 12/964,830 2011-0086066 8,414,884 Methods To Increase Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 12/964,830 2011-0086066 8,414,884 Methods To Increase Transgene Expressing Suppressors Of The Eukaryotic Type I Interferon Response US 13/858,289 2013-0224242 8,658,136 Methods To Increase The Eukaryotic Type I Interferon Response US 13/858,289 2013-0224242 8,658,136 Methods To Increase The Transgene Expressing Suppression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response JP 2010-524977 5665541 Methods To Increase The Transgene Expressing Suppressors Of Eukaryotic Type I Interferon Response JP 2010-524977 5665541	189107.00811	Methods To Increase Transgene	SN	12/558,137	2010-0003219	7,883,696	Issued
Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response JP 2010-524977 Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response		Expression From Bacterial-Based		(9/11/09)	(1/7/10)	(2/8/11)	
Suppressors Of The Eukaryotic Type I Interferon Response 2011-0086066 8,414,884 Methods To Increase Transgene US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based (12/10/10) (4/14/11) (4/9/13) Delivery Systems By Co-Expressing US 12/858,289 2013-0224242 8,658,136 Suppressors Of The Eukaryotic Type I US 13/858,289 2013-0224242 8,658,136 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Expressors Of The Eukaryotic Type I (4/8/13) (8/29/13) (2/25/14) Interferon Response JP 2010-524977 5665541 Expression From Bacterial-Based JP 2010-524977 5665541 Delivery System By Co-Expressing JP 2010-524977 5665541 Suppressors Of Eukaryotic Type I (12/19/14) (12/19/14)		Delivery Systems By Co-Expressing					
Interferon Response US 12/964,830 2011-0086066 8,414,884 Methods To Increase Transgene US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based (12/10/10) (4/14/11) (4/9/13) Delivery Systems By Co-Expressing US 13/858,289 2013-0224242 8,658,136 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Expressors Of The Eukaryotic Type I (4/8/13) (8/29/13) (2/25/14) Interferon Response JP 2010-524977 565541 Expression From Bacterial-Based JP 2010-524977 565541 Delivery System By Co-Expressing JP 2010-524977 565541 Suppressors Of Eukaryotic Type I (12/19/14) (12/19/14)		Suppressors Of The Eukaryotic Type I					
Methods To Increase Transgene US 12/964,830 2011-0086066 8,414,884 Expression From Bacterial-Based (12/10/10) (4/14/11) (4/9/13) Delivery Systems By Co-Expressing (12/10/10) (4/14/11) (4/9/13) Suppressors Of The Eukaryotic Type I US 13/858,289 2013-0224242 8,658,136 Expression From Bacterial-Based US 13/858,289 2013-0224242 8,658,136 Delivery Systems By Co-Expressing (4/8/13) (8/29/13) (2/25/14) Suppressors Of The Eukaryotic Type I Interferon Response 19 2010-524977 5665541 Expression From Bacterial-Based 1P 2010-524977 5665541 Delivery System By Co-Expressing 1P 2010-524977 5665541 Suppressors Of Eukaryotic Type I (12/19/14) (12/19/14)		Interferon Response					
Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response	189107.00821	Methods To Increase Transgene	SN	12/964,830	2011-0086066	8,414,884	Issued
Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response		Expression From Bacterial-Based		(12/10/10)	(4/14/11)	(4/9/13)	
Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response		Delivery Systems By Co-Expressing					
Interferon Response Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response JP 2010-524977 Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response		Suppressors Of The Eukaryotic Type I					
Methods To Increase TransgeneUS13/858,2892013-02242428,658,136Expression From Bacterial-Based(4/8/13)(8/29/13)(2/25/14)Delivery Systems By Co-Expressing(4/8/13)(8/29/13)(2/25/14)Suppressors Of The Eukaryotic Type I(8/29/13)(2/25/14)Interferon ResponseJP2010-524977565541Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I(9/12/08)(12/19/14)Interferon Response(12/19/14)		Interferon Response					
Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response	189107.00841	Methods To Increase Transgene	SN	13/858,289	2013-0224242	8,658,136	Issued
Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response		Expression From Bacterial-Based		(4/8/13)	(8/29/13)	(2/25/14)	
Suppressors Of The Eukaryotic Type I Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response		Delivery Systems By Co-Expressing					
Interferon Response Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response JP 2010-524977 (9/12/08) (12/19/14)		Suppressors Of The Eukaryotic Type I					
Methods To Increase The TransgeneJP2010-524977566541Expression From Bacterial-Based(9/12/08)(12/19/14)Delivery System By Co-ExpressingSuppressors Of Eukaryotic Type IInterferon ResponseInterferon Response		Interferon Response					
g (9/12/08)	189107.00804	Methods To Increase The Transgene	JP	2010-524977		5665541	Issued
Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response		Expression From Bacterial-Based		(9/12/08)		(12/19/14)	
Suppressors Of Eukaryotic Type I Interferon Response		Delivery System By Co-Expressing					
Interferon Response		Suppressors Of Eukaryotic Type I					
		Interferon Response					

Table A.4.8 Family 009

Acid And Method Of Immunizing An Individual Against Malaria	Recombinant Antigenic Peptide, Nucleic	180107 00005 Recombinant Antigonic Polymential	Constituents which elicit cell Mediated	189107.00904 Malaria Vaccine Compositions And	-	Constituents Which Elicit Cell Mediated	189107.00901 Malaria Vaccine Compositions And		Number	Docket Title
	cleic		ated	JP		ated	SU			Country
	(1/12/09)	DI 0005720_3	(1/12/09)	2010-543174		(5/5/11)	12/863,040	(Filing date)	Number	Application
	(11/21/17)	31/10				(8/25/11)	2011-0206714	(Publication date)	Number	Publication
			(//11/14)	55/36/9		(5/20/14)	8,728,492	(Issue Date)	Number	Patent
	reliquig	Dending		Issued			Issued			Status

Table A.4.9 Family 010

			189107.01001	Docket Number
Infection And Reactivation From The Latent Or Persistent State	Latent Mycobacterium Tuberculosis	Protecting Against The Establishment Of	Generation Of New BCG Vaccine Strains	Title
			SN	Country
		(11/13/07)	11/939,144	Country Application Number (Filing date)
		(5/14/09)	2009-0123492	Publication Number (Publication date)
		(5/3/11)	7,935,354	Patent Number (Issue Date)
			Issued	Status

Table A.4.10 Family 012

Docket Number	Title	Country	Application	Publication	Patent	Status
			Number	Number	Number	
			(Filing date)	(Publication date)	(Issue Date)	
189107.01201	Stable, Spray Dryed, Immunogenic,	SN	13/321,048	2012-0058162	9,610,343	Issued
	Viral Compositions		(11/17/11)	(3/8/12)	(4/4/17)	
189107.01211	Stable, Spray Dryed, Immunogenic,	SN	15/438,881	2018-0015158		Pending
	Viral Compositions		2/22/17	(1/18/18)		
189107.01203	Stable, Spray Dried Immunogenic	EP	10778366.4	EP 2432502	EP 2432502	lssued
	Viral Compositions		5/20/10	(3/28/12)	(1/3/18)	
189107.01206	Stable, Spray Dried Immunogenic	CN	201610217396.4			Pending
	Viral Compositions		4/8/16			
189107.01207	Stable, Spray Dried Immunogenic	H	17100694.0	HK1229210		Pending
	Viral Compositions		1/9/17	(11/17/17)		

Table A.4.11 Family 014

	(3/23/16)	(1/18/16)		Of Using The Same		
Pending	CN105431166	201480040735.5	CN	Tuberculosis Compositions And Methods	189107.01405	
	(9/23/16)	(12/24/15)		Of Using The Same		
Pending	P2016-529223A	2016-523852	JP	Tuberculosis Compositions And Methods	189107.01404	
	(5/4/16)	(12/23/15)		Of Using The Same		
Pending	3013364	14817274.5	ΕP	Tuberculosis Compositions And Methods	189107.01403	
	(12/25/14)	(6/24/14)		Of Using The Same		
Pending	2014-0377300	14/313,694	SN	Tuberculosis Compositions And Methods	189107.01401	
	date)					
(Issue Date)	(Publication	(Filing date)				
Number	Number	Number				
Patent Status	Publication	Application	Country	Title	Docket Number	

Table A.4.12 Family 015

189107.01502		189107.01501	Docket Number
Vaccines For Tuberculosis		Recombinant Cytomegalovirus Vectors As	Title
₩ C	5	S	Country
(6/21/17)	(6/21/17)	15/628,921	Application Number (Filing date)
	(1/18/18)	2018-0016599	Publication Number (Publication date)
			Patent Number (Issue Date)
12/22/18		Pending	Status

Table A.4.13 Family 016

	189107.01602		189107.01601	Docket Number
Treating Or Preventing Tuberculosis	Tuberculosis Compositions And Methods Of	Treating Or Preventing Tuberculosis	Tuberculosis Compositions And Methods Of	Title
	WO		SN	Country
(6/16/17)	PCT/US17/37824	(6/16/17)	15/624,853	Application Number (Filing date)
		(12/21/17)	2017-0362284	Publication Patent Number Numb (Publication (Issue date)
				Patent Number (Issue Date)
12/16/18	NP due		Pending	Status

Table A.4.14 Family 018

TRADEMARKS:

NONE

189107.01800	Docket Number
189107.01800 Tuberculosis Antigen Cassettes	Title
SU	Country
62/573,432 (10/17/17)	Application Number (Filing date)
	Publication Patent Number Number (Publication date) (Issue Date)
Pending	Status

PATENT REEL: 047219 FRAME: 0567

RECORDED: 10/18/2018